Latest Observability News

Lakes Blue Energy has wrapped up drilling at its Wombat-5 well in Victoria’s Gippsland Basin, setting the stage for critical gas flow testing to assess commercial potential.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.

Sky Metals has reported upgraded assay results from its Tallebung Tin Project in NSW, revealing multiple new shallow, high-grade tin and silver mineralisation zones. A major drilling campaign of over 100 holes is poised to begin imminently, aiming to expand and upgrade the resource.

Newmont Corporation announces the retirement of CEO Tom Palmer at year-end 2025, with President and COO Natascha Viljoen stepping up as the first female CEO in the company’s century-long history.

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Somerset Minerals reports multiple wide zones of visible copper mineralisation from Phase-2 drilling at its Coppermine Project in Nunavut, Canada, with assays pending. The results extend known mineralisation over 150m below surface and set the stage for a major drilling scale-up.

Athena Resources has reported outstanding assay and metallurgical results from its Byro South drilling program, revealing high-quality magnetite mineralisation with iron grades exceeding 68%. The company is now advancing towards a maiden resource estimate that could reshape the economics of its Byro Magnetite Project.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Dreadnought Resources has revealed a significant rare earth element discovery at its Stinger niobium deposit within the Gifford Creek Carbonatite, marking a new high-grade target in its Mangaroon Critical Metals project.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.